A 68-year-old man is presents to the emergency department with chest pain and shortness of breath for the past 2 hours. He was recently discharged from the hospital following a hip fracture. He has a history of chronic kidney disease stage 3b. A CT pulmonary angiogram shows the presence of an acute pulmonary embolism. He is started on a continuous intravenous infusion of unfractionated heparin.
Which of the following best describes the primary mechanism by which this medication exerts its anticoagulant effect?
The correct answer is:
A) Binding to antithrombin III to accelerate the inactivation of thrombin and factor Xa
Unfractionated Heparin (UFH) is a heterogeneous mixture of glycosaminoglycans. Its primary mechanism involves binding to antithrombin III (ATIII) via a specific pentasaccharide sequence. This binding induces a conformational change in ATIII that increases its ability to inactivate coagulation enzymes, specifically thrombin (Factor IIa) and Factor Xa, by several thousand-fold. Because UFH consists of long polysaccharide chains, it can act as a scaffold that physically bridges ATIII to thrombin. This allows it to inhibit both IIa and Xa equally (a 1:1 ratio). In contrast, low-molecular-weight heparin (LMWH) has shorter chains that are mostly unable to bridge to thrombin, making LMWH more selective for Factor Xa inhibition.
Answer choice B: Direct inhibition of the active site of thrombin, is incorrect. This describes the mechanism of direct thrombin inhibitors (DTIs) such as argatroban, bivalirudin, and dabigatran. These agents do not require antithrombin III as a cofactor to work.
Answer choice C: Inhibition of gamma-carboxylation, is incorrect. This is the mechanism of warfarin. Warfarin interferes with the Vitamin K epoxide reductase (VKOR) enzyme, preventing the activation of Factors II, VII, IX, and X.
Answer choice D: Prevention of platelet aggregation via P2Y12, is incorrect. This describes antiplatelet agents like clopidogrel, prasugrel, and ticagrelor. These drugs inhibit primary hemostasis rather than the secondary hemostasis coagulation cascade.
Answer choice E: Selective inhibition of factor Xa via a pentasaccharide sequence, is incorrect. While heparin contains this sequence, selective inhibition is the hallmark of fondaparinux. Fondaparinux is a synthetic pentasaccharide that is too short to bridge ATIII to thrombin, resulting in pure Factor Xa inhibition.
Key Learning Point
Unfractionated Heparin works by activating antithrombin III, leading to the neutralization of thrombin (IIa) and Factor Xa. It is monitored using the partial thromboplastin time (PTT). A key clinical advantage of UFH is its rapid onset and short half-life, making it ideal for patients who may need procedures or those with advanced kidney disease, as it is cleared by the reticuloendothelial system rather than the kidneys.
